 |
|
Risk of Venous Thrombosis With Use of Current Low-Dose Oral Contraceptives Is Not Explained by Diagnostic Suspicion and Referral Bias
Kitty W. M. Bloemenkamp, MD;
Frits R. Rosendaal, MD;
Harry R. Büller, MD;
Frans M. Helmerhorst, MD;
Louisa P. Colly, MD;
Jan P. Vandenbroucke, MD
Arch Intern Med. 1999;159:65-70.
Background The magnitude of the relative risk of venous thrombosis caused by low-dose oral contraceptive use is still debated because previous studies might have been affected by diagnostic suspicion and referral bias.
Methods We conducted a case-control study in which the effect of diagnostic suspicion and referral bias was excluded. The study was performed in 2 diagnostic centers to which patients with clinically suspected deep vein thrombosis of the leg were referred. History of oral contraceptive use was obtained before objective testing for thrombosis. Young females with an objective diagnosis of deep vein thrombosis were considered case patients, and those who were referred with the same clinical suspicion but who had no thrombosis served as control subjects. Participants were seen between September 1, 1982, and October 18, 1995: 185 consecutive patients and 591 controls aged 15 to 49 years with a first episode of venous thrombosis and without malignant neoplasms, pregnancy, or known inherited clotting defects.
Results The overall odds ratio for oral contraceptive use was 3.2 (95% confidence interval [CI], 2.3-4.5); after adjustment for age, family history of venous thrombosis, calendar time, and center, the odds ratio was 3.9 (95% CI, 2.6-5.7). In the idiopathic group (120 patients and 413 controls, excluding recent surgery, trauma, or immobilization), the odds ratio for oral contraceptive use was 3.8 (95% CI, 2.5-5.9); after adjustment, the odds ratio was 5.0 (95% CI, 3.1-8.2).
Conclusions In this study, in which patients and controls were subject to the same referral and diagnostic procedures, we found similar relative risk estimates for oral contraceptive use as in previous studies. We conclude that diagnostic suspicion and referral bias did not play an important role in previous studies and that the risk of venous thrombosis with use of current brands of oral contraceptives still exists.
From the Departments of Obstetrics, Gynecology, and Reproductive Medicine (Drs Bloemenkamp and Helmerhorst), and Clinical Epidemiology (Drs Rosendaal and Vandenbroucke), and the Thrombosis and Hemostasis Research Centre (Dr Rosendaal), University Hospital Leiden, Leiden; and the Centre for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre of the University of Amsterdam (Dr Büller), and the Amsterdam Thrombosis Service and Laboratory for General Practitioners (Dr Colly), Amsterdam, the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard et al.
BMJ 2009;339:b2890-b2890.
ABSTRACT
| FULL TEXT
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
van Hylckama Vlieg et al.
BMJ 2009;339:b2921-b2921.
ABSTRACT
| FULL TEXT
Travel and Venous Thrombosis: An Exercise in Thinking About Bias
Vandenbroucke et al.
ANN INTERN MED 2009;151:212-213.
FULL TEXT
Venous thromboembolism in women
Rathbun
Vasc Med 2008;13:255-266.
ABSTRACT
Minor Injuries as a Risk Factor for Venous Thrombosis
van Stralen et al.
Arch Intern Med 2008;168:21-26.
ABSTRACT
| FULL TEXT
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
Vandenbroucke et al.
ANN INTERN MED 2007;147:W-163-W-194.
ABSTRACT
| FULL TEXT
Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review
Gomes and Deitcher
Arch Intern Med 2004;164:1965-1976.
ABSTRACT
| FULL TEXT
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial
Kemmeren et al.
Blood 2004;103:927-933.
ABSTRACT
| FULL TEXT
Combined Estrogen-Progestin Oral Contraceptives
Martinelli et al.
NEJM 2004;350:307-308.
FULL TEXT
Combination Estrogen-Progestin Oral Contraceptives
Petitti
NEJM 2003;349:1443-1450.
FULL TEXT
Prescribing Oral Contraceptives for Women Older Than 35 Years of Age
Seibert et al.
ANN INTERN MED 2003;138:54-64.
ABSTRACT
| FULL TEXT
Female Hormones and Thrombosis
Rosendaal et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:201-210.
ABSTRACT
| FULL TEXT
Hypercoagulability: Too Many Tests, Too Much Conflicting Data
Bauer et al.
ASH Education Book 2002;2002:353-368.
ABSTRACT
| FULL TEXT
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren et al.
BMJ 2001;323:131-131.
ABSTRACT
| FULL TEXT
Oral Contraceptives and the Risk of Venous Thrombosis
Vandenbroucke et al.
NEJM 2001;344:1527-1535.
FULL TEXT
Lack of Objectivity in the Debate Concerning Third-Generation Oral Contraceptives and Venous Thrombosis
Egermayer et al.
Arch Intern Med 2001;161:484-485.
FULL TEXT
An Epidemiologic Study of Risk Factors for Deep Vein Thrombosis in Medical Outpatients: The Sirius Study
Samama and for the Sirius Study Group
Arch Intern Med 2000;160:3415-3420.
ABSTRACT
| FULL TEXT
Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database
Farmer et al.
BMJ 2000;321:477-479.
ABSTRACT
| FULL TEXT
Ischemic Stroke Risk With Oral Contraceptives: A Meta-analysis
Gillum et al.
JAMA 2000;284:72-78.
ABSTRACT
| FULL TEXT
Higher Risk of Venous Thrombosis During Early Use of Oral Contraceptives in Women With Inherited Clotting Defects
Bloemenkamp et al.
Arch Intern Med 2000;160:49-52.
ABSTRACT
| FULL TEXT
Gestodene, Desogestrel, and Venous Thromboembolism: A Little Risk after a Long Look
Walker
J. Clin. Endocrinol. Metab. 1999;84:1825-1828.
FULL TEXT
|
